Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
17
pubmed:dateCreated
2010-9-2
pubmed:abstractText
The discovery of aurora kinases as essential regulators of cell division has led to intense interest in identifying small molecule aurora kinase inhibitors for the potential treatment of cancer. A high-throughput screening effort identified pyridinyl-pyrimidine 6a as a moderately potent dual inhibitor of aurora kinases -A and -B. Optimization of this hit resulted in an anthranilamide lead (6j) that possessed improved enzyme and cellular activity and exhibited a high level of kinase selectivity. However, this anthranilamide and subsequent analogues suffered from a lack of oral bioavailability. Converting the internally hydrogen-bonded six-membered pseudo-ring of the anthranilamide to a phthalazine (8a-b) led to a dramatic improvement in oral bioavailability (38-61%F) while maintaining the potency and selectivity characteristics of the anthranilamide series. In a COLO 205 tumor pharmacodynamic assay measuring phosphorylation of the aurora-B substrate histone H3 at serine 10 (p-histone H3), oral administration of 8b at 50 mg/kg demonstrated significant reduction in tumor p-histone H3 for at least 6 h.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1520-4804
pubmed:author
pubmed-author:BakAnnetteA, pubmed-author:BeXuhaiX, pubmed-author:BellonSteveS, pubmed-author:BushTammy LTL, pubmed-author:CeeVictor JVJ, pubmed-author:ChengAlan CAC, pubmed-author:ChungGraceG, pubmed-author:CoatsSteveS, pubmed-author:DeakHolly LHL, pubmed-author:EdenPatrick MPM, pubmed-author:GallantPaul LPL, pubmed-author:Geuns-MeyerStephanie DSD, pubmed-author:GuYanY, pubmed-author:HanestadKellyK, pubmed-author:HodousBrian LBL, pubmed-author:HuangXinX, pubmed-author:KendallRichard LRL, pubmed-author:LinMin-Hwa JasmineMH, pubmed-author:MorrisonMichael JMJ, pubmed-author:NguyenHanh NHN, pubmed-author:OlivieriPhilip RPR, pubmed-author:PatelVinod FVF, pubmed-author:PaytonMarcM, pubmed-author:RadinskyRobertR, pubmed-author:RomeroKarinaK, pubmed-author:RosePaul EPE, pubmed-author:RossSandraS, pubmed-author:SchenkelLaurie BLB, pubmed-author:SunJi-RongJR, pubmed-author:TangJinJ, pubmed-author:ZhaoHuilinH
pubmed:issnType
Electronic
pubmed:day
9
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6368-77
pubmed:dateRevised
2011-7-11
pubmed:meshHeading
pubmed-meshheading:20684549-Administration, Oral, pubmed-meshheading:20684549-Animals, pubmed-meshheading:20684549-Antineoplastic Agents, pubmed-meshheading:20684549-Biological Availability, pubmed-meshheading:20684549-Blood Proteins, pubmed-meshheading:20684549-Cell Line, Tumor, pubmed-meshheading:20684549-Drug Screening Assays, Antitumor, pubmed-meshheading:20684549-Female, pubmed-meshheading:20684549-Histones, pubmed-meshheading:20684549-Humans, pubmed-meshheading:20684549-Male, pubmed-meshheading:20684549-Mice, pubmed-meshheading:20684549-Mice, Nude, pubmed-meshheading:20684549-Microsomes, Liver, pubmed-meshheading:20684549-Models, Molecular, pubmed-meshheading:20684549-Neoplasm Transplantation, pubmed-meshheading:20684549-Phthalazines, pubmed-meshheading:20684549-Protein Binding, pubmed-meshheading:20684549-Protein-Serine-Threonine Kinases, pubmed-meshheading:20684549-Pyridines, pubmed-meshheading:20684549-Pyrimidines, pubmed-meshheading:20684549-Rats, pubmed-meshheading:20684549-Rats, Sprague-Dawley, pubmed-meshheading:20684549-Structure-Activity Relationship, pubmed-meshheading:20684549-Transplantation, Heterologous
pubmed:year
2010
pubmed:articleTitle
Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
pubmed:affiliation
Department of Medicinal Chemistry, Amgen Inc., 360 Binney Street, Cambridge, Massachusetts 02142 and Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA. vcee@amgen.com
pubmed:publicationType
Journal Article, In Vitro